ReviewJournal of clinical microbiology2019
Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria.
Review in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 136 citations in OpenAlex.
- Fatal coinfection by Mycobacterium fortuitum and Epicoccum sp. with concurrent severe coccidial enteritis in an olive ridley sea turtle (Lepidochelys olivacea).Veterinary research communications · 2026Article
- Deferoxamine Exhibits Antimicrobial and Immunomodulatory Activity AgainstInternational journal of molecular sciences · 2026Article
- Antibiotic dose-response curves can measure antibiotic activity againstAntimicrobial agents and chemotherapy · 2026Article
- Vertebral osteomyelitis caused by nontuberculous mycobacteria: a case series of 23 patients and a review of 108 cases in the literature.BMC infectious diseases · 2026Review
- Enhanced In Vitro Stability of Bedaquiline with Ascorbic Acid and Pyruvate During Long-Term Incubation inAntibiotics (Basel, Switzerland) · 2026Article
- Bloodstream Infection Caused by Mycobacterium neoaurum in a Primary Central Nervous System Lymphoma Patient with Toxic Epidermal Necrolysis.Internal medicine (Tokyo, Japan) · 2026Article
- Rifamycin-, macrolide-, and ethambutol-free combinations to treatThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2026Article
- Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes.Nature microbiology · 2026Article
- Draft genome sequence of a non-tuberculous Mycobacterium strain isolated from a clinical urine sample.Access microbiology · 2026Article
- Species Distribution and Antimicrobial Susceptibility Profiles of Non-Tuberculous Mycobacteria in Nanjing, Jiangsu Province, China: A Three-Year Retrospective Study.Infection and drug resistance · 2026Article
- Antibiotic dose-response curves can measure antibiotic activity againstbioRxiv : the preprint server for biology · 2025Article
- Article
- Distribution of nontuberculous Mycobacteria among presumptive drug resistance tuberculosis patients from a ministry of health drug resistance surveillance program, in western Kenya.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Review of the Canadian Nontuberculous Mycobacterial Disease Landscape-Challenges and Opportunities.Tropical medicine and infectious disease · 2025Review
- Luciferase reporter mycobacteriophage (TM4::Journal of clinical microbiology · 2025Article
- Antimicrobial resistance mechanisms in non-tuberculous mycobacteria.Folia microbiologica · 2025Review
- Article
- The Brief Case: Complexity of laboratory diagnosis ofJournal of clinical microbiology · 2025Review
- Diagnostics, resistance and clinical relevance of non-tuberculous mycobacteria unidentified at the species level by line probe assays: a bi-national study.Annals of clinical microbiology and antimicrobials · 2025Article
- Severe Mycobacterium chelonae Infection Following Dermal Filler Injection: A Diagnostic and Therapeutic Challenge.Cureus · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recommendations for first-line and second-line drug testing and organism group, specific methodologies, and reporting recommendations have been addressed by the Clinical and Laboratory Standards Institute (CLSI) and are important in the selection of appropriate antimicrobial treatment regimens for nontuberculous mycobacteria (NTM) disease. This review also includes recent information on new antimicrobials proposed for the treatment of NTM but not yet addressed by the CLSI and molecular (gene sequencing) methods associated with the detection of antimicrobial resistance of two major therapeutic antimicrobials, clarithromycin and amikacin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.